Evidence map›Paper›PMID 40597815›Full record

ArticleBMC cancer2025

Gut markers for metastatic melanoma receiving immunotherapy.

Guoping Ou, Juhua Gou, Hongmu Ou, Hailin Zheng, Yuanying Zhu, Jingjing Li, Xiaohua Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guoping OuDepartment of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfengdong Road, Guangzhou, 510060, P.R. China. ouguop@sysucc.org.cn.
Juhua GouChongqing Liangjiang New Area Traditional Chinese Medicine Hospital, Chongqing, P.R. China.
Hongmu OuChongqing Shapingba Community Health Service Center, Chongqing, P.R. China.
Hailin ZhengDepartment of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfengdong Road, Guangzhou, 510060, P.R. China.
Yuanying ZhuDepartment of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfengdong Road, Guangzhou, 510060, P.R. China.
Jingjing LiMelanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. lijingj@sysucc.org.cn.
Xiaohua LiuDepartment of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfengdong Road, Guangzhou, 510060, P.R. China. liuxh@sysucc.org.cn.

Funding

Foundation of Sun Yat-sen University Cancer Center for Distinguished Young Scholar PT04180201National Natural Science Foundation of China 81802725
6 · The paper itself

Abstract

backgroundThis project aimed to discover independent gut markers of immunotherapy based on qPCR method.

methods80 metastatic melanoma patients receiving immunotherapy were enrolled in this study, and the relative abundance of 41 gut markers was worked out by a newly established qPCR method. The HR of these gut markers was calculated using Rstudio-coxph. The associations between these 41 gut markers and age as well as treatment-course were analyzed by heatmap, linear-regression or VIF. Markers for Cox prediction model were selected according to the results of HR, VIF and LASSO regression. Nomogram, calibration curves for nomogram and stratified survival analysis were used to observe the predictive performance of the prediction model and related gut markers.

resultsBlo

conclusionsFurther detection of gut markers (Amc and Bvu) could better predict patients' responsiveness to immunotherapy.

Indexed as

Biomarkers, TumorGastrointestinal MicrobiomeImmunotherapyMelanomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNomogramsPrognosisBiomarkers, TumorGut markersImmunotherapyMelanomaPrognosisqPCR

Identifiers

PMID40597815
PMCPMC12211910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.